Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2016 14:45 ET | Source: Levi & Korsinsky, LLP

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Seres Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 28, 2016 – MCRB

NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased shares of Seres Therapeutics, Inc....
October 26, 2016 10:30 ET | Source: INNATE PHARMA

INNATE PHARMA : Encouraging initial results for IPH4102 presented at the Third World Congress of Cutaneous Lymphomas

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} encouraging initial results for IPH4102...
October 26, 2016 08:30 ET | Source: Altimmune, Inc.

Altimmune Announces Poster Presentation of HepTcell Program at 2017 Keystone Symposia Conference

GAITHERSBURG, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that a poster detailing the design and preclinical evaluation of its...
October 26, 2016 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of KRN23 in Pediatric Patients with X-Linked Hypophosphatemia (XLH)

NOVATO, Calif, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
October 26, 2016 08:00 ET | Source: Acasti Pharma Inc.

Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre

LAVAL, QUÉBEC--(Marketwired - Oct. 26, 2016) - Acasti Pharma (NASDAQ:ACST)(TSX VENTURE:APO) today announced that the United States Patent and Trademark Office issued Acasti a patent...
October 26, 2016 08:00 ET | Source: Selecta Biosciences Inc

Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout

First Immunotherapeutic Candidate to Leverage Selecta’s Proprietary Synthetic Vaccine Particle (SVP™) PlatformSEL-212 Targeting Unmet Needs of Chronic Refractory and Tophaceous Gout PatientsInitial...
October 26, 2016 08:00 ET | Source: Argos Therapeutics Inc.

Argos Therapeutics Announces CEO Jeff Abbey Elected to NCBIO Board of Directors

DURHAM, N.C., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
October 26, 2016 07:30 ET | Source: Cellceutix Corporation

Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications

BEVERLY, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
October 26, 2016 07:00 ET | Source: Actinium Pharmaceuticals

Actinium Pharmaceuticals Announces New Hires As Supply Chain Organization Expands To Accommodate Growth

- Incoming specialists to focus on Quality Control and Quality Assurance Aspects of Supply Chain NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM)...
October 26, 2016 06:40 ET | Source: Research and Markets

Global Bromine Strategic Business Report 2014-2022: Focus on Flame Retardants, Drilling Fluids, Organic Intermediates, Water-Treatment Chemicals, and Other Applications

Dublin, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Bromine - Global Strategic Business Report" report to their offering. ...